Connect to other sites within the UBM Medica Network
Long-Term Results Confirm Superior Outcomes of Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Long-term results of the CROSS study have confirmed that neoadjuvant chemoradiotherapy added to surgery should be the standard of care in esophageal or esophagogastric junction carcinoma.
Angiogenic Factors Linked to Esophageal Cancer Outcomes
A retrospective analysis found that high expression levels of two angiogenic factors were associated with poor prognosis in esophageal cancer.
FDA Approves Drug Combo for Gastric/GEJ Adenocarcinoma
The FDA approved ramucirumab (Cyramza) in combination with paclitaxel for treating patients with advanced gastric or gastroesophageal junction adenocarcinoma.
MicroRNA Expression Predictive of Outcomes in Esophageal Cancer
Measuring expression of several microRNAs were significantly predictive of complete pathologic response to treatment in patients with esophageal adenocarcinoma.
Best to Stage Esophageal Cancer After Neoadjuvant Chemo
The stage of esophageal adenocarcinomas after neoadjuvant chemotherapy is predictive of outcomes, rather than the stage determined prior to therapy.
Gene Mutation Test Could Aid Esophageal Cancer Diagnosis
New research has identified specific gene mutations that occur in precancerous esophageal lesions, a finding which was then put into use with a simple non-endoscopic test.
Preop Chemoradiation Fails to Improve Survival in Early Esophageal Cancer
Neoadjuvant chemoradiotherapy did not improve resection rates or survival outcomes in patients with early-stage, locally advanced esophageal cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.